Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Amaranta D. Craig"'
Autor:
Blair McNamara, Rosa Guerra, Jennifer Qin, Amaranta D. Craig, Lee-may Chen, Madhulika G. Varma, Jocelyn S. Chapman
Publikováno v:
Gynecologic Oncology Reports, Vol 38, Iss , Pp 100870- (2021)
Objectives: To evaluate the impact of bowel resection at the time of interval cytoreductive surgery on survival. Methods: We identified patients with advanced ovarian cancer who underwent neoadjuvant chemotherapy and interval cytoreductive surgery be
Externí odkaz:
https://doaj.org/article/811d727f44634b28a40a6df1c17fdb0a
Autor:
Sean Cronin, Nishat Ahmed, Amaranta D. Craig, Stephanie King, Min Huang, Christina S. Chu, Gina M. Mantia-Smaldone
Publikováno v:
Diagnostics, Vol 12, Iss 3, p 560 (2022)
Non-Gestational Ovarian Choriocarcinoma (NGOC) is an extremely rare ovarian tumor, with an incidence of less than 0.6% of malignant ovarian germ cell tumors. Its close pathologic resemblance to Gestational Ovarian Choriocarcinoma (GOC), however, requ
Externí odkaz:
https://doaj.org/article/2161229ddbc3431885de0531e39fb9c4
Publikováno v:
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
Ovarian cancer is the most costly and deadly of the gynecologic malignancies. Financial toxicity from out-of-pocket costs for direct care and medications as well as indirect costs from lost income is a growing challenge in oncology. The aim of this r
Autor:
Jennifer Qin, Blair McNamara, Rosa Alisa Guerra, Madhulika G. Varma, Jocelyn S. Chapman, Lee-may Chen, Amaranta D. Craig
Publikováno v:
Gynecologic Oncology Reports, Vol 38, Iss, Pp 100870-(2021)
Gynecologic Oncology Reports
Gynecologic Oncology Reports
Highlights • Bowel resection is associated with decreased three-year survival. • Bowel resection does not impact progression free survival. • Bowel resection is associated with significant peri-operative complication. • Sequelae of peri-opera
Publikováno v:
Future oncology (London, England). 17(34)
Aims: This study evaluated primary treatment modalities in advanced ovarian cancer according to sociodemographic characteristics and characterized chemotherapy regimens used. Methods: This was a retrospective study of newly diagnosed advanced ovarian
Autor:
Amma F. Agyemang, Kathryn Alsop, George Au-Yeung, Susan Bates, David D. Bowtell, Elizabeth L. Christie, Christopher B. Cole, Denise C. Connolly, Amaranta D. Craig, Anna deFazio, Sian Fereday, Antonio Fojo, Alison E. Freimund, Michael Friedlander, Bo Gao, Paul R. Harnett, Therese Hoang, Carrie D. House, Cristina Mapagu, Kathleen N. Moore, Tania Moujaber, Kunle O. Odunsi, Suraj Peri, Kathleen Pishas, Debra L. Richardson, Valerie L. Sodi, Alice Soragni, Meghna S. Trivedi, Christina R. Washington, Jennifer A. Waters
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da12a6cf1d7651139d6ada0fdc29d311
https://doi.org/10.1016/b978-0-12-819840-7.09988-x
https://doi.org/10.1016/b978-0-12-819840-7.09988-x
Ovarian cancer remains the most lethal gynecologic cancer. Research over the past several decades has shown that ovarian cancer is a complex and heterogeneous group of cancers that exhibit different disease biology, often present at advanced stage an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1890f3fa41e28e62860ea870e0903a9a
https://doi.org/10.1016/b978-0-12-819840-7.00012-1
https://doi.org/10.1016/b978-0-12-819840-7.00012-1
Publikováno v:
Gynecologic Oncology. 159:e29-e30
Autor:
Gina Mantia-Smaldone, Nathaniel L. Jones, Enrique Hernandez, Joanne Xiu, Sharon Wu, Jubilee Brown, Amaranta D. Craig, Annelise M. Wilhite
Publikováno v:
Journal of Clinical Oncology. 39:5579-5579
5579 Background: Hormone receptor (HR) positivity has been reported as a good prognostic indicator in endometrial cancer. This study investigated estrogen receptor (ER) and progesterone receptor (PR) positivity as indicators of platinum response and
Autor:
Joanne Xiu, Gina Mantia-Smaldone, Rodney P. Rocconi, Matthew A. Powell, Robert W. Holloway, N.L. Jones, Jubilee Brown, Sharon Wu, Amaranta D. Craig, Annelise M. Wilhite, Wolfgang Michael Korn, Thomas J. Herzog, Enrique Hernandez
Publikováno v:
Journal of Clinical Oncology. 39:5590-5590
5590 Background: Uterine serous carcinoma (USC) is an aggressive subtype of endometrial cancer with poor prognosis and limited treatment options. Immune-oncology (IO) agents have shown promise USC, however data is limited regarding which patients ben